Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23229065 | 0.75 | KMT2A (0.35) | — | |
| SCHEMBL4076792 | 0.67 | KMT2A (0.41) | CYP3A4TSHR | |
| SCHEMBL26597056 | 0.66 | JAK2 (0.41) | CYP3A4TSHR | |
| SCHEMBL24995507 | 0.63 | PDE10A (0.31) | — | |
| SCHEMBL23229059 | 0.62 | ALDH1A1 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL12775635 | 0.61 | ELANE (0.42) | — | |
| SCHEMBL21931157 | 0.61 | MAPT (0.44) | CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL23229066 | 0.59 | SMN1; SMN2 (0.36) | CYP3A4CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL122923 | 0.59 | KDM4E (0.41) | TSHR | |
| SCHEMBL4076727 | 0.59 | PARP1 (0.46) | CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218257-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218257-A1 | NOVEL NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | CYP3A4 1883/4885CYP2D6 1961/4885CYP2C9 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.